PILA.ST
PILA PHARMA AB (publ) [PILA.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PILA.ST Stock Summary
In the News
PILA.ST Financial details
Company Rating
-
Market Cap
44.85M
Income
-12.13M
Revenue
1.46M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
28 Feb 2024
P/E
-0.8
Forward P/E
-
PEG
0.11
P/S
17.36
P/B
34.56
P/C
-
P/FCF
-5.25
Quick Ratio
0.37
Current Ratio
0.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.65
EPS next Y
-
EPS next Q
-
EPS this Y
-81.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-10.09%
Revenue last 5Y
33.39%
Revenue Q/Q
-
EPS Q/Q
-25.75%
-
-
-
-
SMA20
-
SMA50
-25%
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
-961%
ROE
-846%
ROC
-36.76%
Gross Margin
100%
Oper. Margin
-1846%
Profit Margin
-2165%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.992-4.17
52W High
-
52W Low
-
RSI
43
Rel Volume
0.71
Avg Volume
28.93K
Volume
20.46K
Perf Week
-9.41%
Perf Month
-14.43%
Perf Quarter
-40.83%
Perf Half Y
-42.45%
-
-
-
-
Beta
0.725
-
-
Volatility
0.13%, 0.2%
Prev Close
-0.17%
Price
2.935
Change
-2.81%
Company Profile
- Volume Average 28.93K
- Market Capitalization 44.85M
- Employee 1
- CEO Ms. Dorte Xenia Gram
- Headquarters Malmö,SE
- IPO Date 2021-07-15
-
Website
https://pilapharma.com 
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
